Penn Medicine Abramson Cancer Center


 

UPenn 2020 ASCO Updates on ET in MBC: Is Fulvestrant + Alpelisib Effective in Patients With PIK3CA Mutations Previously Treated With AI + CDK4/6 Inhibition?

131 views
December 1, 2020
Comments 0
Login to view comments. Click here to Login